N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling.

Junjie XuZhe WanMinyue TangZhongjie LinShi JiangLin JiKirill GorshkovQijiang MaoShunjie XiaDong CenJunhao ZhengXiao LiangXiujun Cai

Published in: Molecular cancer (2020)

This work indicates a novel mechanism for maintaining sorafenib resistance and is a proof-of-concept study for targeting circRNA-SORE in sorafenib-treated HCC patients as a novel pharmaceutical intervention for advanced HCC.

Keyphrases

end stage renal disease
newly diagnosed
randomized controlled trial
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
cancer therapy
patient reported